Therapeutics/Diagnostics News

Pegozafermin significantly improved fibrosis without worsening of nonalcoholic steatohepatitis, and vice versa, with similar efficacy reported at weekly and biweekly dosing intervals, according to late-breaker data at EASL Congress.

Older age, male sex and increased hepatitis B surface antigen correlated with a higher risk for hepatic flare after nucleos(t)ide analogue withdrawal in patients with chronic HBV, according to data at the EASL Congress.

In a Healio video exclusive, Pam Vig, PhD, highlights new data on Livmarli for the treatment of patients with pruritus due to progressive familial intrahepatic cholestasis and Alagille syndrome, which were presented at EASL Congress.

Researchers reported no difference in rates of infection, rebleeding and mortality when antibiotic prophylaxis was given to stable patients with Child-Pugh A cirrhosis and acute variceal bleeding.

Both 80 mg and 100 mg doses of resmetirom achieved liver biopsy endpoints at 52 weeks in patients with nonalcoholic steatohepatitis and had a safety profile consistent with previous reports, according to primary MAESTRO-NASH trial results.

The Dialive device significantly reduced severity of endotoxemia and improved albumin function in patients with acute-on-chronic liver failure and appears safe with careful patient monitoring, according to data in the Journal of Hepatology.

The prospect of managing a lifelong disease can be daunting, and many patients with chronic conditions struggle with consistent health monitoring, treatment adherence and implementing the changes needed to manage their disease.

The addition of peripartum antiviral prophylaxis to reduce neonatal hepatitis B virus infection could have “substantial extra health benefits,” although decreased diagnostic costs are needed to make this strategy cost-effective.

Motorized spiral enteroscopy may have a technical advantage over single-balloon enteroscopy in reaching mid-small bowel lesions and examining a greater length of bowel in a shorter period of time in patients with suspected Crohn’s disease.

The FDA has approved Bylvay for the treatment of cholestatic pruritus due to Alagille syndrome in patients aged 12 months or older, according to an Ipsen Biopharmaceuticals press release.